Cargando…

Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease

The neuroprotective and nootropic activities of the amide form (AF) of the HLDF-6 peptide (TGENHR-NH(2)) were studied in transgenic mice of the B6C3-Tg(APPswe,PSEN1de9)85Dbo (Tg+) line (the animal model of familial Alzheimer’s disease (AD)). The study was performed in 4 mouse groups: group 1 (study...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogachouk, A. P., Storozheva, Z. I., Telegin, G. B., Chernov, A. S., Proshin, A. T., Sherstnev, V. V., Zolotarev, Yu. A., Lipkin, V. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A.I. Gordeyev 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662275/
https://www.ncbi.nlm.nih.gov/pubmed/29104777
_version_ 1783274606074789888
author Bogachouk, A. P.
Storozheva, Z. I.
Telegin, G. B.
Chernov, A. S.
Proshin, A. T.
Sherstnev, V. V.
Zolotarev, Yu. A.
Lipkin, V. M.
author_facet Bogachouk, A. P.
Storozheva, Z. I.
Telegin, G. B.
Chernov, A. S.
Proshin, A. T.
Sherstnev, V. V.
Zolotarev, Yu. A.
Lipkin, V. M.
author_sort Bogachouk, A. P.
collection PubMed
description The neuroprotective and nootropic activities of the amide form (AF) of the HLDF-6 peptide (TGENHR-NH(2)) were studied in transgenic mice of the B6C3-Tg(APPswe,PSEN1de9)85Dbo (Tg+) line (the animal model of familial Alzheimer’s disease (AD)). The study was performed in 4 mouse groups: group 1 (study group): Tg+ mice intranasally injected with the peptide at a dose of 250 μg/kg; group 2 (active control): Tg+ mice intranasally injected with normal saline; group 3 (control 1): Tg- mice; and group 4 (control 2): C57Bl/6 mice. The cognitive functions were evaluated using three tests: the novel object recognition test, the conditioned passive avoidance task, and the Morris water maze. The results testify to the fact that the pharmaceutical substance (PhS) based on the AF of HLDF-6 peptide at a dose of 250 μg/kg administered intranasally efficiently restores the disturbed cognitive functions in transgenic mice. These results are fully consistent with the data obtained in animal models of Alzheimer’s disease induced by the injection of the beta-amyloid (βA) fragment 25-35 into the giant-cell nucleus basalis of Meynert or by co-injection of the βA fragment 25-35 and ibotenic acid into the hippocampus, and the model of ischemia stroke (chronic bilateral occlusion of carotids, 2VO). According to the overall results, PhS based on AF HLDF-6 was chosen as an object for further investigation; the dose of 250 μg/kg was used as an effective therapeutic dose. Intranasal administration was the route for delivery.
format Online
Article
Text
id pubmed-5662275
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher A.I. Gordeyev
record_format MEDLINE/PubMed
spelling pubmed-56622752017-11-03 Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease Bogachouk, A. P. Storozheva, Z. I. Telegin, G. B. Chernov, A. S. Proshin, A. T. Sherstnev, V. V. Zolotarev, Yu. A. Lipkin, V. M. Acta Naturae Research Article The neuroprotective and nootropic activities of the amide form (AF) of the HLDF-6 peptide (TGENHR-NH(2)) were studied in transgenic mice of the B6C3-Tg(APPswe,PSEN1de9)85Dbo (Tg+) line (the animal model of familial Alzheimer’s disease (AD)). The study was performed in 4 mouse groups: group 1 (study group): Tg+ mice intranasally injected with the peptide at a dose of 250 μg/kg; group 2 (active control): Tg+ mice intranasally injected with normal saline; group 3 (control 1): Tg- mice; and group 4 (control 2): C57Bl/6 mice. The cognitive functions were evaluated using three tests: the novel object recognition test, the conditioned passive avoidance task, and the Morris water maze. The results testify to the fact that the pharmaceutical substance (PhS) based on the AF of HLDF-6 peptide at a dose of 250 μg/kg administered intranasally efficiently restores the disturbed cognitive functions in transgenic mice. These results are fully consistent with the data obtained in animal models of Alzheimer’s disease induced by the injection of the beta-amyloid (βA) fragment 25-35 into the giant-cell nucleus basalis of Meynert or by co-injection of the βA fragment 25-35 and ibotenic acid into the hippocampus, and the model of ischemia stroke (chronic bilateral occlusion of carotids, 2VO). According to the overall results, PhS based on AF HLDF-6 was chosen as an object for further investigation; the dose of 250 μg/kg was used as an effective therapeutic dose. Intranasal administration was the route for delivery. A.I. Gordeyev 2017 /pmc/articles/PMC5662275/ /pubmed/29104777 Text en Copyright ® 2017 Park-media Ltd. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bogachouk, A. P.
Storozheva, Z. I.
Telegin, G. B.
Chernov, A. S.
Proshin, A. T.
Sherstnev, V. V.
Zolotarev, Yu. A.
Lipkin, V. M.
Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title_full Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title_fullStr Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title_full_unstemmed Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title_short Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer’s Disease
title_sort studying the specific activity of the amide form of hldf-6 peptide using the transgenic model of alzheimer’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662275/
https://www.ncbi.nlm.nih.gov/pubmed/29104777
work_keys_str_mv AT bogachoukap studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT storozhevazi studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT telegingb studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT chernovas studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT proshinat studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT sherstnevvv studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT zolotarevyua studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease
AT lipkinvm studyingthespecificactivityoftheamideformofhldf6peptideusingthetransgenicmodelofalzheimersdisease